drugset / Trial / NCT05541107
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
Phase 3
Unknown
270 enrolled
Matinas BioPharma Nanotechnologies, Inc.
University of Minnesota · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This pivotal, confirmatory trial seeks to independently verify the results observed in the EnACT Phase II Stage 2 trial (MB-70007).
Timeline
- Start
- 2023-01
- Primary completion
- 2024-10
- Completion
- 2025-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amphotericin B | Unknown | — | Oral |
| Comparator | Amphotericin B | Unknown | — | Intravenous |